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Summary
Background A dose of 30 mg/kg of azithromycin is recommended for treatment of yaws, a disease targeted for global 
eradication. Treatment with 20 mg/kg of azithromycin is recommended for the elimination of trachoma as a public 
health problem. In some settings, these diseases are co-endemic. We aimed to determine the efficacy of 20 mg/kg of 
azithromycin compared with 30 mg/kg azithromycin for the treatment of active and latent yaws.
Methods We did a non-inferiority, open-label, randomised controlled trial in children aged 6–15 years who were 
recruited from schools in Ghana and schools and the community in Papua New Guinea. Participants were enrolled 
based on the presence of a clinical lesion that was consistent with infectious primary or secondary yaws and a positive 
rapid diagnostic test for treponemal and non-treponemal antibodies. Participants were randomly assigned (1:1) to 
receive either standard-dose (30 mg/kg) or low-dose (20 mg/kg) azithromycin by a computer-generated random 
number sequence. Health-care workers assessing clinical outcomes in the field were not blinded to the patient’s 
treatment, but investigators involved in statistical or laboratory analyses and the participants were blinded to treatment 
group. We followed up participants at 4 weeks and 6 months. The primary outcome was cure at 6 months, defined as 
lesion healing at 4 weeks in patients with active yaws and at least a four-fold decrease in rapid plasma reagin titre 
from baseline to 6 months in patients with active and latent yaws. Active yaws was defined as a skin lesion that was 
positive for Treponema pallidum ssp pertenue in PCR testing. We used a non-inferiority margin of 10%. This trial was 
registered with ClinicalTrials.gov, number NCT02344628.
Findings Between June 12, 2015, and July 2, 2016, 583 (65·1%) of 895 children screened were enrolled; 292 patients were 
assigned a low dose of azithromycin and 291 patients were assigned a standard dose of azithromycin. 191 participants had 
active yaws and 392 had presumed latent yaws. Complete follow-up to 6 months was available for 157 (82·2%) of 
191 patients with active yaws. In cases of active yaws, cure was achieved in 61 (80·3%) of 76 patients in the low-dose group 
and in 68 (84·0%) of 81 patients in the standard-dose group (difference 3·7%; 95% CI −8·4 to 15·7%; this result did not 
meet the non-inferiority criterion). There were no serious adverse events reported in response to treatment in either 
group. The most commonly reported adverse event at 4 weeks was gastrointestinal upset, with eight (2·7%) participants 
in each group reporting this symptom.
Interpretation In this study, low-dose azithromycin did not meet the prespecified non-inferiority margin compared 
with standard-dose azithromycin in achieving clinical and serological cure in PCR-confirmed active yaws. Only a 
single participant (with presumed latent yaws) had definitive serological failure. This work suggests that 20 mg/kg of 
azithromycin is probably effective against yaws, but further data are needed.
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Introduction
Yaws, a neglected tropical disease caused by Treponema 
pallidum ssp pertenue, remains an important public 
health problem in remote communities of 14 countries 
in Africa, Asia, and the western Pacific.1,2 Yaws is closely 
genetically related to syphilis, but these diseases can be 
differentiated on the basis of clinical features and 
through molecular testing. Yaws predominantly affects 
children younger than 15 years and transmission occurs 
by direct contact with a person with an early infectious 
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lesion. The early lesions of primary and secondary yaws 
predominantly manifest as chronic cutaneous ulcers and 
papillomas.1 A serological diagnosis of yaws requires the 
detection of both treponemal and non-treponemal 
antibodies.1 Alongside clinical improve ment, non-
treponemal titres are expected to fall following treatment 
with effective antibiotics. More recently, point-of-care 
serological tests and PCR assays have become available 
to aid diagnosis.3–6 If left untreated, yaws can progress to 
destructive lesions of the bone and soft tissues.
Long-acting injectable penicillin has been the mainstay 
of yaws treatment since WHO and the United Nations 
Children’s Fund led campaigns in the 1950s. In 2012, a 
randomised controlled trial (RCT)7 in Papua New Guinea 
showed that a single dose of 30 mg/kg of azithromycin 
(maximum 2 g) was non-inferior to benzathine benzyl-
penicillin for the treatment of yaws. Following this 
finding, which was later confirmed by a similar study in 
Ghana,8 WHO developed a new eradication strategy for 
yaws that involved mass treatment of the community 
with azithromycin.9 Pilot studies10 suggest that azithro-
mycin mass treatment is very effective at reducing the 
prevalence of infection and disease.
Mass treatment of the community with azithromycin is 
also key to WHO’s SAFE strategy for the elimination of 
trachoma as a public health problem;11 however, the 
dose of azithromycin used in trachoma programmes 
(20 mg/kg, maximum 1 g) is lower than the recommended 
dose for treatment of yaws. This difference in recom-
mendations is potentially problematic because, in areas 
where trachoma and yaws are co-endemic,12 although 
mass treatment for trachoma elimination programmes 
might aid efforts to eradicate yaws if the dose used is 
effective against yaws, it could have negative consequences 
if the lower dose for trachoma treatment is subtherapeutic 
and results in more rapid selection of macrolide-resistant 
strains of T pallidum ssp pertenue. Azithromycin resistance 
spread rapidly in syphilis, caused by the genetically related 
T pallidum ssp pallidum.13–15 Establishing definitive data on 
the efficacy of low-dose azithromycin has therefore been 
identified as a priority by the International Task Force for 
Disease Eradication and partners.16,17 Studies18,19 in the 
Solomon Islands have shown that mass administration of 
azithromycin to eliminate trachoma has significant effects 
on the prevalence of both active and latent yaws; however, 
to date, no formal trials have compared the efficacy of the 
two doses. If a 20 mg/kg dose was shown to effectively 
treat yaws, this finding could potentially reduce both the 
costs of eradication and the incidence of adverse events 
associated with mass drug administration. This result 
might also allow synergistic treatment of yaws via 
trachoma elimination programmes (or vice versa) in areas 
where the diseases are co-endemic.16
Although a lower dose of azithromycin might be 
effective at treating the relatively more metabolically 
active treponemes in a skin lesion, it might be less 
effective in latent infections, in which the bacteria are 
postulated to be less metabolically active.1 Since treatment 
of both active and latent yaws is crucial for yaws 
eradication,20 it is important that the efficacy of treatment 
with a low dose of azithromycin be established both for 
active and latent yaws.
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Research in context
Evidence before this study
We searched PubMed using the terms “yaws”, “treponema”, 
“pallidum pertenue”, and “azithromycin”, without date or 
language restrictions. Trials conducted in both 
Papua New Guinea and Ghana have shown that single-dose 
30 mg/kg (maximum 2 g) azithromycin is an effective 
treatment for yaws. A lower dose of azithromycin (20 mg/kg, 
maximum 1 g) is recommended by WHO for treatment of 
trachoma. Observational studies in countries that are 
co-endemic for trachoma and yaws have shown that mass 
administration of azithromycin for trachoma reduces the 
prevalence of both active and latent yaws in the community, 
but no previous prospective controlled trial has evaluated the 
relative efficacy of low-dose versus standard-dose azithromycin 
for the treatment of yaws.
Added value of this study
We investigated the relative efficacy of low-dose and 
standard-dose azithromycin in the treatment of yaws. By 
stratifying the trial population on the basis of PCR positivity for 
bacteria in samples extracted from the patients’ lesions, we 
provide data on clinical and serological outcomes in active and 
latent yaws. In participants with active yaws, clinical cure 
occurred in a similar proportion of participants following 
treatment with low-dose and standard-dose azithromycin. 
In participants with active yaws who received low-dose 
azithromycin, the proportion who achieved serological cure 
(and therefore the composite primary outcome) did not meet 
the non-inferiority margin. There was a lower than anticipated 
serological cure response at 6 months, which reduced the 
overall power of the study. In participants with presumed latent 
yaws, serological cure responses did not differ between the 
treatment groups. Our findings, considered alongside existing 
observational data, imply that standard-dose and low-dose 
azithromycin are likely to be equally effective for patients 
with yaws.
Implications of all the available evidence
20 mg/kg azithromycin seems to be effective in treating yaws. 
Due to the smaller than anticipated primary study population 
of Treponema pallidum ssp pertenue PCR-positive participants 
and the lower than expected serological cure response in both 
groups, further data are needed before low-dose azithromycin 
can be unequivocally adopted as the standard of care.
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We therefore conducted an RCT in Ghana and 
Papua New Guinea, the countries that report the most 
cases of yaws globally,2 to determine whether the efficacy 
of low-dose azithromycin was non-inferior to standard-
dose azithromycin in the treatment of yaws.
Methods
Study design and participants
We did a randomised, controlled, open-label non-
inferiority trial in four districts of Ghana and one district 
of Papua New Guinea (figure 1). Participants were 
recruited from schools in Ghana and schools and the 
community in Papua New Guinea and they were treated 
at their location of recuitment. None of these districts 
had previously received mass treatment with azithro-
mycin for trachoma, but West Akim had received some 
mass treatment for yaws in 2013. Before study 
commencement, district study teams and officials of the 
national yaws eradication programmes of each country 
ran educational sessions to inform the selected 
communities about the study.
We identified children aged 6–15 years (the age range in 
which yaws incidence peaks) with a clinical lesion that 
was consistent with infectious primary or secondary yaws, 
which comprised at least one ulcerative lesion or 
papilloma, as described in the WHO yaws booklet.21 We 
collected a finger-prick blood sample from each child. A 
rapid diagnostic test (dual path platform [DPP] syphilis 
screen and confirm assay; Chembio Diagnostics, Medford, 
NY, USA) was done, which detects both treponemal and 
non-treponemal antibodies.22 Children with a clinically 
suspicious lesion and a dual-positive rapid diagnostic test 
(positive for both treponemal and non-treponemal tests; 
appendix 1) met the inclusion criteria and were invited to 
enrol in the study. Children were excluded if they had a 
known allergy to azithromycin or macrolides, had received 
treatment with an antibiotic effective against T pallidum in 
the past 3 months, or had another contraindication to 
treatment with the study drug.
Before study commencement, teams underwent 
standardised training in clinical diagnosis of yaws, 
performance of the rapid diagnostic test, collection of 
blood and lesion samples, management of adverse 
events, and completion of documentation in line with 
the Good Clinical Practice guidelines.
Written informed consent was obtained from the 
parent or guardian of each participant. Consent was also 
obtained from children who could provide it. The study 
was approved by the ethics committees of WHO (RPC 
720), the London School of Hygiene & Tropical Medicine 
(London, UK; 8832), the US Centers for Disease Control 
and Prevention (CDC; Atlanta, GA, USA; 6746/7285), the 
Ghana Health Service (Accra, Ghana; 13/11/14), the 
Papua New Guinea National Department for Health 
(Port Moresby, Papua New Guinea; MRAC 14.31), and the 
Papua New Guinea Institute of Medical Research 
(Goroka, Papua New Guinea; 1504). The study was done 
in accordance with the Declaration of Helsinki and 
was monitored by an independent Data and Safety 
Monitoring Board.
Randomisation and masking
Eligible children were randomly assigned to either a 
low-dose (20 mg/kg, maximum 1 g) or standard-dose 
(30 mg/kg, maximum 2 g) group. Randomisation was 
performed in blocks of four, by use of a computer-
generated random number sequence that was generated 
by the trial statistician (CB) at the London School of 
Hygiene & Tropical Medicine. Allocation was concealed 
from investigators by use of opaque, sealed, sequentially 
numbered envelopes that were opened after the study 
team had enrolled a participant. Health-care workers 
assessing clinical outcomes in the field were not masked 
to the patient’s treatment group but patients and 
investigators performing statistical or laboratory analyses 
of samples were masked to treatment allocation. Study 
allocations are listed in appendix 2.
Procedures
Children were seen at baseline for enrolment, initial data 
collection, and treatment, and again for follow-up at 
4 weeks and at 6 months. At each visit, children received 
a standardised skin examination, during which the type 
and location of any yaws-like lesions were recorded. In 
participants with more than one yaws-like lesion, the 
largest lesion was identified as the lesion-of-interest for 
sample collection and determination of healing at follow-
up. Photographs were taken of the lesion-of-interest and 
the DPP results at each timepoint. All clinical data were 
collected directly into smartphones with the LINKS 
software package.23
A 5 mL sample of serum was obtained from all enrolled 
participants at baseline and at the 6-month follow-up. 
Additionally, at baseline, a single swab sample was 
collected from the target lesion and placed into 1·2 mL 
of AssayAssure transport medium (Thermo Fisher 
Nkwanta Karkar
Ghana Papua New Guinea
Ayensuano
Upper West Akim
West Akim
0 80 160 240 320 400 km 0 340 680 1020 1860 km
N
Figure 1: Districts of study recruitment in Ghana and Papua New Guinea
See Online for appendix 1
See Online for appendix 2
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Scientific, Waltham, MA, USA) as previously described.3 
At 4 weeks, if there had been no healing of the lesion, a 
repeat swab sample was obtained and the participant was 
offered treatment with benzathine benzylpenicillin. At 
6 months, if the lesion was still not fully healed, a repeat 
swab sample was obtained and the participant was 
offered treatment with benzathine benzylpenicillin, or 
referred to the local health facility for further manage-
ment, or both.
Serum and lesion samples were transported on dry ice 
to the CDC laboratories in Atlanta, GA, USA. Serum 
samples were tested with the Serodia T pallidum passive 
particle agglutination test (Fujirebio Diagnostics, 
Malvern, PA, USA) and a quantitative rapid plasma 
reagin (RPR) test (Alere, Waltham, MA, USA). Because 
Haemophilus ducreyi commonly causes skin lesions that 
can be clinically difficult to distinguish from the lesions 
of yaws infections, and Buruli ulcer is co-endemic in 
both countries,4,24,25 two real-time multiplex PCR assays 
for the presence of T pallidum ssp pertenue, H ducreyi, 
and Mycobacterium ulcerans were done on swab samples, 
as previously described.3,24 The T pallidum PCR used has 
previously been shown to have an analytical sensitivity of 
ten copies per sample.3 The multiplex PCR assays also 
incorporated an amplification of the human RNA 
polymerase gene to confirm the integrity of samples and 
the absence of PCR inhibition. Additionally, all samples 
were tested by use of an additional multiple PCR for 
mutations associated with azithromycin resistance.26 The 
use of PCR in the current study allowed delineation of 
the effect of the two dosing strategies in both participants 
with active yaws (positive in a PCR analysis for T pallidum 
ssp pertenue in a lesion) and in participants with 
presumed latent yaws and a different cause of the current 
skin lesion (negative in a PCR analysis for T pallidum ssp 
pertenue in a lesion).
All participants were treated with azithromycin, which 
was administered as a single oral dose. WHO purchased 
azithromycin from Medopharm (India) and DPP syphilis 
screen and confirm rapid diagnostic tests from Chembio 
Diagnostics. Other study materials were provided by 
WHO and CDC. A small snack was provided so that 
individuals could eat before treatment. The study team 
directly observed treatment. Participants were observed 
for 1 hour following treatment to monitor for immediate 
adverse events. If vomiting occurred within this time, the 
child was treated again. Children who did not meet 
inclusion criteria for the study also received a standard 
30 mg/kg dose of azithromycin, in accordance with 
WHO recommendations, and their ulcers were dressed. 
Any side-effects were monitored and managed by the 
study team or patients were referred to the district 
hospital for further treatment. Immediate adverse events 
were documented at the time of drug administration 
while the participant remained under observation. 
Participant-reported adverse events were documented at 
the 4-week follow-up visit.
Outcomes
The primary endpoint was cure at 6 months of treatment. 
Cure was a composite outcome of both clinical cure and 
serological cure. Clinical cure was defined as complete or 
partial resolution of the lesion by 4 weeks. Clinical failure 
was defined as no evidence of healing at the 4-week 
follow-up visit (appendix). Serological cure was defined 
as a decrease in the quantitative RPR titre between 
baseline and 6 months of greater than 4-fold (eg, from 
1:32 to 1:8) or RPR seroreversion by 6 months. The 
primary endpoint was measured in participants with 
both serologically and PCR-confirmed yaws.
Serological cure and clinical cure were analysed 
separately as secondary outcomes. Serological failure 
was defined as an increase in RPR titre between baseline 
and 6 months of at least 4-fold (eg, from 1:4 to 1:16). 
Participants with a negative RPR at baseline were 
excluded from the analyses of both the composite 
primary outcome and the secondary outcomes because 
serological outcomes could not be assessed in this patient 
group. Participants with a missing baseline or 6-month 
RPR result or a missing baseline lesion PCR result were 
also excluded from all analyses.
Statistical analysis
The study was designed to assess whether treatment 
with 20 mg/kg of azithromycin (maximum 1 g) was 
non-inferior to treatment with 30 mg/kg (maximum 2 g) 
of azithromycin for the primary outcome in participants 
who were PCR-positive for T pallidum ssp pertenue at 
baseline. A prespecified non-inferiority margin of 
10% was used. Non-inferiority was defined as an upper 
bound of the two-sided 95% CI for the difference in 
proportions (ie, proportion of participants in the 
30 mg/kg treatment group who achieved cure minus the 
proportion of participants in the 20 mg/kg treatment 
group who achieved cure) of less than or equal to 10%. 
This margin was selected to reflect the maximum 
difference in efficacy that would allow the lower dose to 
remain acceptable for use in yaws eradication efforts. For 
secondary outcomes, non-inferiority was also assessed 
with the use of a two-sided 95% CI for the between-group 
difference. All confidence intervals were calculated by 
use of the Agresti-Caffo method.27
The primary analysis was restricted to participants with 
lesion samples that were positive by PCR for T pallidum 
ssp pertenue at baseline. We did pre-planned secondary 
analyses of this population (patients who were PCR-
positive for T pallidum ssp pertenue at baseline) by 
country of recruitment. Further pre-planned analyses 
were done on the following secondary study populations: 
(1) all study participants, regardless of baseline PCR 
status; and (2) participants who had a negative T pallidum 
ssp pertenue PCR result at baseline. Among participants 
with a negative T pallidum ssp pertenue PCR result at 
baseline, we separately evaluated the proportion 
achieving clinical cure in patients who tested positive for 
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H ducreyi DNA and in patients who tested negative 
for H ducreyi DNA in their lesion at baseline.
To investigate the effects of missing data, we did a 
sensitivity analysis using multiply imputed data on the 
primary analysis population of participants with 
T pallidum ssp pertenue DNA detected at baseline. The 
imputation model included all baseline and outcome 
variables, and was implemented by use of the method of 
multiple chained equations.28
Assuming 95% efficacy of standard treatment, a 
non-inferiority margin of 10%, a type I error rate of 5%, 
and 10% loss to follow-up, we calculated that a total of 
220 PCR-confirmed cases of yaws (ie, 110 cases per study 
group) would be required for the primary analysis. Based 
on PCR data collected in previous studies, we calculated 
that 524 individuals with clinically suspicious yaws lesions 
and a positive point-of-care serological test would be 
needed to achieve this sample size. Analyses were 
performed in Stata version 14.0 (StataCorp, College Station, 
TX, USA). This trial is registered with ClinicalTrials.gov, 
number NCT02344628.
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had 
full access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results
Between June 12, 2015, and July 2, 2016, 895 children with 
clinically suspected yaws were screened for enrolment. Of 
these, 583 (65·1%) had a positive DPP point-of-care test 
and were enrolled (figure 2). 400 (68·6%) participants were 
enrolled in Ghana and 183 (31·4%) were enrolled in 
Papua New Guinea. 292 participants were randomly 
assigned to the low-dose group and 291 to the standard-
dose group (figure 2). Baseline clinical and serological 
895 children with suspected yaws 312 exclusions
 33 negative for DPP line 1
 37 negative for DPP line 2
 192 negative for DPP lines 1 and 2
 46 missing DPP lines 1 or 2
 2 unable to take blood
 1 unwell at screening
 1 other
583 DPP dual-positive participants random
14 excluded
 2 missing baseline RPR
 2 missing clinical data
 10 missing 6-month RPR
196 negative in TP-PCR
124 negative included
 in study analyses
72 excluded
 5 missing baseline RPR
 50 negative for baseline 
 RPR
 6 missing clinical data
 11 missing 6-month RPR 
200 included in secondary analysis
101 positive in TP-PCR
81 positive included
 in final analysis
81 included in primary
  analysis
   20 excluded
 2 missing baseline RPR
 3 negative for baseline 
 RPR
 4 missing clinical data
 11 missing 6-month RPR 
182 negative in TP-PCR
125 negative included
 in study analyses
57 excluded
 1 missing baseline RPR
 40 negative for baseline 
 RPR
 1 missing clinical data
 15 missing 6-month RPR 
206 included in secondary analysis
90 positive in TP-PCR
76 positive included
in final analysis
76 included in primary
 analysis
6 missing TP-PCR results
292 assigned to low-dose group (20 mg/kg)
8 missing TP-PCR results
291 assigned to standard-dose group 
(30 mg/kg)
Figure 2: Trial profile
DPP=dual path platform, a syphilis screen and confirm assay. TP-PCR= Treponema pallidum PCR. RPR=rapid plasma reagin.
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characteristics were similar between the two groups: the 
median age of participants was 10 years (IQR 8–12) and 
412 (70·7%) participants were male (table 1).
Baseline PCR was positive for T pallidum ssp pertenue 
alone in 161 participants (27·6%; 75 in the low-dose 
group and 86 in the standard-dose group) and for both 
T pallidum ssp pertenue and H ducreyi in 30 participants 
(5·1%; 15 in each group). These two groups constituted 
the population for the primary study analysis. The 
remaining 392 participants were included in secondary 
analyses; they comprised 150 (25·7%) participants with 
only H ducreyi-positive lesions by PCR (75 in each 
group), 228 (39·1%) participants with negative PCR 
results for all pathogens tested for (121 in the low-dose 
group and 107 in the standard-dose group), and 
14 (2·4%) participants whose baseline PCR data were 
missing (six in the low-dose group and eight in the 
standard-dose group). No samples tested positive for 
M ulcerans.
In the primary analysis of participants with 
PCR-confirmed active yaws (table 2) the non-inferiority 
criterion was not met for the composite primary outcome 
of clinical and serological cure at 6 months. The primary 
outcome was achieved in 68 (84·0%) of 81 participants in 
the standard-dose group and 61 (80·3%) of 76 participants 
in the low-dose group (absolute difference 3·7%, 95% CI 
−8·4 to 15·7%). The proportion achieving clinical cure 
did not differ significantly between groups. The 
proportion achieving serological cure was slightly higher 
in the standard-dose group, but this difference was not 
significant (table 2).
Clinical healing of lesions in both groups is shown in 
figure 3. Of the 28 participants who did not achieve 
serological cure at 6 months (15 in the low-dose group 
and 13 in the high-dose group), none met the definition 
of serological failure: all had a non-significant RPR 
change at 6 months, of which 18 showed only a 2-fold 
decrease in RPR titre (seven in the low-dose group and 
11 in the standard-dose group), seven showed no change 
in RPR titre (six in the low-dose group and one in the 
standard-dose group), and three showed a 2-fold increase 
in RPR titre (two in the low-dose group and one in the 
standard-dose group). The proportion of participants 
achieving clinical cure did not significantly differ 
countries, nor did the proportion achieving serological 
cure (table 2; p=0·223). Clinical outcomes were similar 
when assessed at 4 weeks and 6 months (appendix).
No participant with clinical treatment failure had 
detectable T pallidum ssp pertenue DNA in any lesion at 
follow-up. No mutations associated with azithromycin 
resistance in T pallidum were detected at either baseline 
or follow-up.
In the secondary analysis, in which data from all 
participants were analysed regardless of baseline PCR 
status (ie, participants included in the primary analysis 
who were either positive or negative for T pallidum by 
PCR), the primary outcome was achieved in 132 (64·1%) of 
Low-dose group Standard-dose 
group
Difference between groups, % 
(95% CI)*
Overall
Clinical and serological cure at 
6 months
61/76 (80·3%) 68/81 (84·0%) 3·7% (–8·4 to 15·7)
Clinical cure at 4 weeks 76/76 (100·0%) 81/81 (100·0%) 0% (–3·3 to 3·5)
Serological cure at 6 months 61/76 (80·3%) 68/81 (84·0%) 3·7% (–8·4 to 15·7)
Ghana
Clinical and serological cure 46/60 (76·7%) 53/64 (82·8%) 6·1% (–8·1 to 20·2)
Clinical cure at 4 weeks 60/60 (100·0%) 64/64 (100·0%) 0% (–4·2 to 4·4) 
Serological cure at 6 months 46/60 (76·7%) 53/64 (82·8%) 6·1% (–8·1 to 20·2) 
Papua New Guinea
Clinical and serological cure 15/16 (93·8%) 15/17 (88·2%) –5·6% (–26·6 to 17·2) 
Clinical cure at 4 weeks 16/16 (100·0%) 17/17 (100·0%) 0% (–14·3 to 14·9)
Serological cure at 6 months 15/16 (93·8%) 15/17 (88·2%) –5·6% (–26·6 to 17·2) 
Data are n/N (%), unless otherwise specified. *Percentage in standard-dose group minus percentage in low-dose group.
Table 2: Trial outcomes in participants with PCR-confirmed active yaws
Low-dose group (n=292) Standard-dose group (n=291)
Country
Ghana 201 (69%) 199 (68%)
Papua New Guinea 91 (31%) 92 (32%)
Age (years)
Median (IQR) 10·0 (8·0–12·0) 10·0 (8·0–12·0)
Sex
Male 204 (70%) 208 (71%)
Female 88 (30%) 83 (29%)
Number of lesions
Unknown 0 2 (1%)
1 181 (62%) 180 (62%)
2 63 (22%) 63 (22%)
3 20 (7%) 20 (7%)
4 28 (10%) 26 (9%)
Lesion type (of the largest lesion)
Unknown 1 (<1%) 1 (<1%)
Papillomas 51 (17%) 60 (21%)
Ulcer 240 (82%) 230 (79%)
Lesion location (largest lesion)
Unknown 1 (<1%) 1 (<1%)
Face and neck 20 (7%) 15 (5%)
Trunk 1 (<1%) 2 (1%)
Back 4 (1%) 10 (3%)
Arm 27 (9%) 26 (9%)
Leg 239 (82%) 237 (81%)
Serology at baseline
Unknown 7 (2%) 3 (1%)
RPR <1:16 129 (44%) 131 (45%)
RPR ≥1:16 156 (53%) 157 (54%)
Data are number of participants (%), unless otherwise indicated. RPR=rapid plasma reagin.
Table 1: Participant characteristics at baseline
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206 patients assigned to the standard-dose group 
compared with 134 (67·0%) of 200 patients assigned to 
the low-dose group; this result met the non-inferiority 
criterion (absolute difference −3%, 95% CI −12·1 to 6·3). 
In this secondary analysis, the proportion of participants 
achieving clinical cure and the proportion of patients 
achieving serological cure were similar in the low-dose 
group (table 3). The serological cure rate was higher in 
participants with a baseline RPR concentration of 1:16 or 
greater (72·0% in patients with a baseline RPR ≥1:16 vs 
54·2% in patients with a baseline RPR <1:16, p<0·001; 
appendix). Of 139 patients who did not achieve serological 
cure at 6 months (66 in the low-dose group and 73 in the 
high-dose group), only one participant (in the standard-
dose group) had a four-fold RPR titre increase consistent 
with definitive serological failure. Of these participants, 
77 (34 from the low-dose group and 43 from the standard-
dose group) showed only a two-fold decrease in RPR titre, 
47 (26 from the low-dose group and 21 from the standard-
dose group) showed no change to their RPR titre, and 
14 (six from the low-dose group and eight from the 
standard-dose group) had a two-fold increase in RPR titre. 
In the secondary analysis, the proportion of participants 
with T pallidum ssp pertenue PCR-negative lesions at 
baseline who achieved cure was higher in the low-dose 
group, meeting the non-inferiority criterion (table 3). 
The proportion of patients in both study groups who 
achieved clinical cure was high, regardless of whether 
H ducreyi was detected at baseline or not (table 3). 
In the pre-planned analysis on the basis of multiply 
imputed data, the proportions of participants achieving 
cure were 80·8% in the standard-dose group and 
80·2% in the low-dose group (absolute difference 0·5%, 
95% CI −12·2 to 13·3).
There were no serious adverse events reported in 
response to treatment in either group. In the active 
surveillance data collected from participant reports at 
4 weeks, the most commonly reported adverse event was 
gastrointestinal upset, with no significant difference in 
frequency between groups (2·7% vs 2·7%; eight in each 
group; appendix).
We did a post-hoc analysis of 93 individuals with a 
negative RPR at baseline who were excluded from the 
main analyses. This group included three participants in 
the standard-dose group whose lesions at baseline were 
T pallidum ssp pertenue PCR-positive. Of the 93 participants, 
82 (88%) participants had a 6-month RPR result available. 
Four (5%) participants were found to have definitive 
evidence of seroconversion (an RPR titre of 1:2 or higher) 
at 6 months (two from each group), of whom two had a 
T pallidum ssp pertenue PCR-positive lesion at baseline. A 
further seven (9%) participants had a conversion from a 
negative to undiluted positive RPR (four from the low dose 
group and three from the standard-dose group), which 
might represent false-positives, and the remaining 
71 (87%) remained RPR-negative at 6 months (39 from the 
low-dose group and 32 from the standard-dose group).
Discussion
In this randomised, controlled, non-inferiority trial, low-
dose (20 mg/kg) azithromycin did not meet the 
prespecified non-inferiority margin compared with 
standard-dose (30 mg/kg) azithromycin in achieving 
clinical and serological cure in PCR-confirmed active 
yaws. The fact that we did not find non-inferiority of this 
dosage reflects wide confidence intervals around cure 
frequencies, which arose from the smaller than anticipated 
number of PCR-positive cases, and the lower than 
anticipated proportion of participants achieving serological 
cure. Despite this, low-dose azithromycin achieved a 
clinical cure rate of 100% (identical to the standard dose), 
which met the non-inferiority criterion, and a point 
estimate for serological cure of 80%, which, despite not 
meeting the non-inferiority criterion, did not differ 
A
B
Single dose of
20 mg/kg
azithromycin
Lesions before treatment 
Single dose of
30 mg/kg
 azithromycin
Lesions 4 weeks after treatment 
Single dose of
20 mg/kg
azithromycin
Lesions before treatment 
Single dose of
30 mg/kg
azithromycin
Lesions 4 weeks after treatment 
Figure 3: Clinical outcomes of treatment
Clinical healing of lesions from baseline to 4 weeks following treatment with either low-dose or standard-dose 
azithromycin in (A) Papua New Guinea and (B) Ghana.
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significantly from standard-dose treatment (84%). 
Additionally, our pre-planned secondary analyses of all 
individuals regardless of PCR results, and of participants 
who were PCR-negative, both suggested non-inferiority of 
low-dose treatment. These findings, considered together, 
imply that standard-dose and low-dose azithromycin are 
likely to be equally effective for patients with yaws. 
Unfortunately, we were unable to show this unequivocally 
in participants with active yaws in the current study.
The overall proportion of participants achieving 
serological cure at 6 months was lower than anticipated. 
As in previous studies7,8 comparing benzathine benzyl-
penicillin to azithromycin for treatment of yaws, the 
proportion achieving serological cure at 6 months was 
lower in participants enrolled in Ghana than in those 
enrolled in Papua New Guinea, although this difference 
did not reach statistical significance. Two-thirds of our 
participants were enrolled in Ghana, which could partly 
explain the lower overall proportion of participants 
achieving serological cure at 6 months. Geographical 
variation in the outcome of randomised trials is well 
recognised, although it is unclear to us why serological 
cure rates might differ between these two settings. Strain 
differences, host immune responses, and random 
chance could all conceivably contribute. Our study was 
not powered to detect differences in outcomes between 
the two countries, and further studies are thus needed to 
explore the apparent differences in serological responses 
seen following antibiotic treatment.
A strength of our work is the use of baseline PCR to 
stratify participants. This method allows us to explore 
clinical and serological cure rates in both active yaws (in 
T pallidum ssp pertenue PCR-positive lesions) and 
presumed latent yaws (seropositive but PCR-negative for 
T pallidum ssp pertenue). PCR analyses allowed us to 
provide prospective data showing that both standard-dose 
and low-dose azithromycin were 100% effective for the 
clinical cure of skin ulcers caused by H ducreyi, which has 
emerged as a major cause of ulcerative lesions among 
children in tropical settings.4,24,25 The proportion of 
participants achieving clinical cure was also very high in 
lesions for which baseline PCR was negative for both 
T pallidum ssp pertenue and H ducreyi. This finding might 
reflect effective treatment of other ulcers caused by other 
azithromycin-susceptible pathogens, such as Streptococcus 
spp and Staphylococcus aureus, or healing of self-limiting 
skin lesions. Overall, the clinical effects of azithromycin 
seen in this study indicate that mass treatment with 
azithromycin is likely to provide additional benefit beyond 
its effect on yaws, which should be helpful for community 
acceptability. Our data also provide reassurance that the 
efficacy of low-dose azithromycin is not significantly 
different to standard-dose azithromycin for the serological 
cure of individuals with presumed latent yaws.29
A major limitation of this study is the smaller than 
anticipated proportion of individuals with active yaws 
who were enrolled in the study. The percentage of 
participants with T pallidum ssp pertenue PCR-positive 
lesions was slightly lower than that reported in some 
previous studies.3,4 Although this discrepancy might 
reflect a variation in the underlying causes of skin ulcer 
disease in the current study, it might also reflect issues 
with the ulcer swabbing technique applied to lesions.
Although a significant number of participants did not 
achieve the per-protocol definition of serological cure by 
6 months, several factors related to interpretation of 
treponemal serology should be considered. First, 
amongst participants not achieving serological cure, only 
one patient had a four-fold increase in RPR titre, 
consistent with definitive serological failure, while 
three other patients had two-fold increases in RPR titre 
during follow-up. We cannot exclude the possibility that 
reinfection occurred during the period of follow-up, 
which might explain the rises in RPR titre in these 
patients. The absence of mutations conferring 
azithromycin resistance at baseline or emerging during 
follow-up in these patients is reassuring. All other 
participants not achieving the per-protocol definition of 
serological cure during the trial did achieve clinical cure 
but had either no change in titre or a two-fold RPR titre 
decrease from baseline to 6 months. It can take at least 
12–24 months for the full amplitude of the RPR titre 
decrease to be expressed after successful treatment, 
particularly in latent yaws.29,30 Extending the follow-up 
period to 12 months or longer could have increased the 
proportion of patients achieving serological cure, 
particularly in participants with presumed latent disease. 
Second, it is possible that some individuals classified as 
having latent infection at baseline (positive serology with 
negative lesion PCR for T pallidum ssp pertenue) and who 
had no significant change in RPR titres at 6 months were 
actually serofast (ie, individuals with a persistent low titre 
of non-treponemal antibodies following successful 
Low-dose group Standard-dose 
group
Difference between 
groups, % (95% CI)*
All yaws serology-positive participants†
Clinical and serological cure 134/200 (67%) 132/206 (64%) −3% (−12·1 to 6·3)
Clinical cure at 4 weeks 200/200 (100%) 204/206 (99%) −1% (−2·8 to 0·9)
Serological cure at 6 months 134/200 (67%) 133/206 (65%) −2% (−11·6 to 6·8)
Yaws serology-positive, Treponema pallidum ssp pertenue PCR-negative at baseline
Clinical and serological cure 73/124 (59%) 64/125 (51%) −8% (−19·8 to 4·7)
Clinical cure at 4 weeks 124/124 (100%) 123/125 (98%) −2% (−4·6 to 1·5)
Serological cure at 6 months 73/124 (59%) 65/125 (52%) −7% (−19·0 to 5·5)
Yaws serology-positive, T pallidum ssp pertenue PCR-negative, and Haemophilus ducreyi PCR-positive
Clinical cure at 4 weeks 51/51 (100%) 51/51 (100%) 0% (−5·2 to 5·2)
Yaws serology-positive, T pallidum ssp pertenue PCR-negative, and H ducreyi PCR-negative
Clinical cure at 4 weeks 73/73 (100%) 72/74 (97%) −3% (−7·7 to 2·5)
Data are n/N (%), unless otherwise specified. *Percentage in standard-dose group minus percentage in low-dose 
group. †All participants with positive serology for yaws (T pallidum particle agglutination and rapid plasma regain 
tests) regardless of the result of their baseline lesion PCR.
Table 3: Trial outcomes in prespecified secondary study populations
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treatment). Unfortunately, since there are no tests 
available that can distinguish serofast status31 from true 
latent infection, it is not possible to accurately determine 
the effect of this phenomenon on the proportion of our 
T pallidum ssp pertenue PCR-negative cases who achieved 
serological cure.
In this RCT, low-dose azithromycin did not meet the 
non-inferiority criterion for serological cure among 
participants with PCR-confirmed active yaws, although 
non-inferiority was shown within the study population 
overall. In both study groups, the clinical cure rate was 
close to 100% and only one patient had definitive 
serological failure following treatment. Although further 
data are needed to unequivocally establish the 
non-inferiority of low-dose azithromycin, the data in this 
study, together with existing observational data, suggest 
that 20 mg/kg of azithromycin is an effective treatment 
for yaws. In co-endemic countries planning mass drug 
administration for trachoma, the current results provide 
reassurance that this will also have a beneficial effect on 
the prevalence of yaws. When azithromycin is co-
administered for trachoma, yaws, or both diseases, close 
monitoring of the effects and for the emergence of drug 
resistance in T pallidum ssp pertenue will be crucial.
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